BioSpace News Archive

Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting - Two oral presentations highlighting new data on DaxibotulinumtoxinA for Injection from the SAKURA Phase 3 program, the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines – - One

Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in Initial Phase 3 results may be available as early as the end of 2020; results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021 If successful, VIR-7831 has the potential to advance outpatient treatment for COVID-19 Patient enrollment underway;

NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T cell immunotherapies, announced today that it has dosed the first patient in its Phase 1/2 clinical trial for NEXI-002

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has formed the COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the clinical development program for the Ii-Key-SARS-CoV-2 vaccine with a special emphasis on development of a safe and effective vaccine for the pediatric population and for pregnant women,

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated multi-state cannabis operator in the United States, today announced a month-long, multi-state fundraising initiative in which proceeds will benefit ten locally-run organizations across the U.S. that cater to the unique needs of the women and families affected by breast cancer

Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s chief medical officer. Dr. Noonberg brings significant industry and clinical experience to Maze as the company works to advance its pipeline. “Sarah is an exceptional leader who has helped guide multiple companies through various sta

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

General Atlantic, a leading global growth equity firm, today announced that Brett Zbar, MD, has joined the firm as a Managing Director and Global Head of Life Sciences.

Financial Condition for Initial $5 Million Tranche of Potential $16 Million Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann

Mesuron Inc. is a US commercial company specializing in the development and fabrication of SQUID-based magnetometers for various applications